| 摘要 |
The present invention relates to the use of TGF-beta antagonists for the treatment, amelioration, and diagnosis of parathyroid-related disorders, e.g., HPT-JT, familial isolated primary hyperparathyroidism (FIPH), and hyperparathyroidism-jaw tumor (HPT-JT) syndrome, as well as its attendant complications. The present invention also relates to the use of modulators of HRPT2 and its related PAF1 complex for the treatment, amelioration, and diagnosis of TGFbeta-related disorders, e.g., pulmonary hypertension, cancer, hypertension, fibrosis, wound healing. Assays of the identification of modulators of HRPT2/PAF1 and SMAD/TGFbeta are also provided.
|
